Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-01-12Clinical Trial Update: Efficacy of Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of MS After a Clinically Isolated Syndrome [Phase 3]
Phase 3 trial update evaluating vitamin D3 (cholecalciferol) for delaying the diagnosis of multiple sclerosis after a clinically isolated sy…
-
CLINICAL_TRIALS trial_result · 2024-01-08Clinical Trial Update: Effects of Oral Cladribine on Remyelination and Inflammation in Multiple Sclerosis Patients [Phase 4]
Phase 4 trial investigating effects of oral cladribine on remyelination and inflammation in relapsing-remitting multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2024-01-05Clinical Trial Update: MS Spinal Mobilisation Study [NA]
A completed clinical trial evaluating spinal mobilisation for multiple sclerosis, with results posted in early 2024.
-
EMA withdrawal · 2023-12-22EMA Revoked: Dimethyl fumarate Teva (dimethyl fumarate) — Teva GmbH
EMA revoked the marketing authorization for Teva's dimethyl fumarate product.
-
EMA withdrawal · 2023-12-22EMA Revoked: Dimethyl fumarate Accord (dimethyl fumarate) — Accord Healthcare S.L.U.
EMA revoked the marketing authorization for Dimethyl fumarate Accord for multiple sclerosis indications.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-12-22Clinical Trial Update: A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis [Phase 2]
Phase 2 trial assessing the safety and efficacy of Elezanumab added to standard of care for relapsing forms of multiple sclerosis; trial com…
-
CLINICAL_TRIALS trial_result · 2023-12-21Clinical Trial Update: A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis [Phase 2]
A Phase 2 trial evaluating elezanumab added to standard of care in progressive multiple sclerosis has completed with results posted in 2023.
-
FDA approval · 2023-12-13FDA Approved: TECFIDERA — Supplemental Application (Biogen Inc.)
FDA approves Biogen's supplemental application for Tecfidera (dimethyl fumarate).
-
FDA approval · 2023-12-13FDA Approved: VUMERITY — Supplemental Application (Biogen Inc.)
FDA approves Biogen's supplemental application for VUMERITY (diroximel fumarate).
-
FDA approval · 2023-12-13FDA Approved: BAFIERTAM — Supplemental Application (Banner Life Sciences LLC)
The FDA approved a supplemental application for BAFIERTAM (monomethyl fumarate) from Banner Life Sciences LLC.
-
CLINICAL_TRIALS trial_result · 2023-12-11Clinical Trial Update: Amantadine and Transcranial Magnetic Stimulation for Treating Fatigue in Multiple Sclerosis [Phase 3]
Phase 3 trial investigating amantadine combined with transcranial magnetic stimulation for fatigue in multiple sclerosis; current status unk…
-
FDA approval · 2023-12-06FDA Approved: MAVENCLAD — Supplemental Application (EMD Serono, Inc.)
The FDA has approved a supplemental application for MAVENCLAD (cladribine) submitted by EMD Serono, Inc.
-
CLINICAL_TRIALS trial_result · 2023-12-04Clinical Trial Update: Non-invasive Transcranial Electrical Stimulation in MS [NA]
A completed clinical trial investigating non-invasive transcranial electrical stimulation for cognitive impairment in multiple sclerosis, wi…
-
CLINICAL_TRIALS trial_result · 2023-12-01Clinical Trial Update: A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS [Phase 3]
Phase 3 trial assessing efficacy, safety, and tolerability of monthly long-acting GA Depot IM injection in relapsing-remitting multiple scle…
-
EMA approval · 2023-11-23EMA Authorised: Betaferon (interferon beta-1b) — Bayer AG
EMA authorised Betaferon (interferon beta-1b) by Bayer AG for multiple sclerosis.
-
FDA approval · 2023-11-16FDA Approved: GILENYA — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for GILENYA (fingolimod HCl) from Novartis Pharmaceuticals Corporation. The action involves a ch…
-
FDA approval · 2023-11-16FDA Approved: COPAXONE — Supplemental Application (Teva Neuroscience, Inc.)
The FDA has approved a supplemental application for COPAXONE (glatiramer acetate) from Teva Neuroscience, Inc.
-
CLINICAL_TRIALS trial_result · 2023-11-09Clinical Trial Update: Phase II Clinical Trial of OCH-NCNP1 [Phase 2]
Phase II clinical trial update for OCH-NCNP1 completed; study conditions include relapsing-remitting and secondary progressive multiple scle…
-
CLINICAL_TRIALS trial_result · 2023-10-27Clinical Trial Update: Aspirin for Exercise in Multiple Sclerosis (ASPIRE) [Phase 3]
Phase 3 clinical trial ASPIRE evaluating aspirin for exercise benefits in multiple sclerosis has completed; results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-10-18Clinical Trial Update: Study of Behavioral Modification Program and Mirabegron to Improve Urinary Urgency in Multiple Sclerosis [Phase 4]
Phase 4 clinical trial evaluating a behavioral modification program in combination with mirabegron to improve urinary urgency in people with…
-
FDA approval · 2023-10-12FDA Approved: BACLOFEN — Supplemental Application (Palmetto Pharmaceuticals Inc.)
FDA approved a supplemental application for baclofen from Palmetto Pharmaceuticals Inc., indicating an update to the drug's existing approva…
-
CLINICAL_TRIALS trial_result · 2023-10-05Clinical Trial Update: Brain Targets in Patients With Bladder Emptying Difficulties [NA]
Clinical trial update with results posted for brain-targeted approaches in patients with neurogenic bladder and multiple sclerosis-related v…
-
CLINICAL_TRIALS trial_result · 2023-09-14Clinical Trial Update: Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS) [Phase 4]
Phase 4 clinical trial evaluating quality of life in subjects with highly active relapsing multiple sclerosis; study completed with results …
-
FDA approval · 2023-09-12FDA Approved: BACLOFEN — Supplemental Application (TruPharma LLC)
FDA approved TruPharma LLC's supplemental application for baclofen, enabling a new generic version to be marketed.
-
CLINICAL_TRIALS trial_result · 2023-09-06Clinical Trial Update: Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714 [Phase 3]
Phase 3 trial exploring ocrelizumab's effect on brain innate immune microglial activation in multiple sclerosis using PET-MRI.